Drug Trial Radar · NCT06297213
R-2487 in Patients With Sjogren's Syndrome (SjD)
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Aug 30, 2029
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Rise Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Conditions
- Sjogren's Syndrome
- Sjögren
- Sjögren Syndrome, Unspecified
Interventions
R-2487Drug
R-2487 DP
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events and their relationship to R-2487 (probiotic) administrationTime frame: Baseline through Week 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Johns Hopkins Jerome L. Greene Sjögren's Syndrome Center Johns Hopkins University - Rheumatology Department
Baltimore, Maryland
University of Michigan - Michigan Medicine
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.